melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 

theraTRACE

Melior Pharmaceuticals

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery psychiatric

Startle Prepulse Inhibition
Pre-pulse inhibition (PPI) is the ability to inhibit the reaction of a subject to a strong startling stimulus (pulse) with a weaker pre-stimulus (pre-pulse).  This model is designed to identify pharmacological agents that disrupt sensorimotor gating in normal animals and improve it in affected animals.  Neurological disorders associated with sensorimotor gating deficits include schizophrenia, post-traumatic stress disorder, obsessive compulsive disorder, Tourette’s syndrome and Alzheimer’s and Huntington’s Diseases. 

      
The data illustrate a significant reduction in startle amplitude in mice treated with Risperidone compared to mice treated with vehicle.  Data are mean ± SEM; **p<0.01 compared to vehicle

If you are interested in learning more about Startle Prepulse Inhibition, please contact models@meliordiscovery.com to start the conversation.